Switch theme
Sign up to access all valuation multiples
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
1984
27.0K+
LTM Revenue $3.8B
LTM EBITDA $1.0B
$10.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dr. Reddy's Laboratories has a last 12-month revenue of $3.8B and a last 12-month EBITDA of $1.0B.
In the most recent fiscal year, Dr. Reddy's Laboratories achieved revenue of $3.2B and an EBITDA of $1.0B.
Dr. Reddy's Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dr. Reddy's Laboratories valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.2B | XXX | XXX | XXX |
| Gross Profit | $1.3B | $1.6B | XXX | XXX | XXX |
| Gross Margin | 46% | 50% | XXX | XXX | XXX |
| EBITDA | $865M | $1.0B | XXX | XXX | XXX |
| EBITDA Margin | 30% | 32% | XXX | XXX | XXX |
| Net Profit | $274M | $523M | XXX | XXX | XXX |
| Net Margin | 10% | 16% | XXX | XXX | XXX |
| Net Debt | $186M | $62.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Dr. Reddy's Laboratories's stock price is INR 1109 (or $13).
Dr. Reddy's Laboratories has current market cap of INR 924B (or $10.7B), and EV of INR 916B (or $10.6B).
See Dr. Reddy's Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.6B | $10.7B | XXX | XXX | XXX | XXX | $0.79 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Dr. Reddy's Laboratories has market cap of $10.7B and EV of $10.6B.
Dr. Reddy's Laboratories's trades at 2.8x LTM EV/Revenue multiple, and 10.3x LTM EBITDA.
Analysts estimate Dr. Reddy's Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Dr. Reddy's Laboratories and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $10.6B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 10.3x | XXX | XXX | XXX |
| P/E | 16.4x | XXX | XXX | XXX |
| P/E/Growth | -3.0x | XXX | XXX | XXX |
| EV/FCF | -126.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDr. Reddy's Laboratories's NTM/LTM revenue growth is 8%
Dr. Reddy's Laboratories's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $42K for the same period.
Over next 12 months, Dr. Reddy's Laboratories's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Dr. Reddy's Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Dr. Reddy's Laboratories and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 36% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $42K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 35% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dr. Reddy's Laboratories acquired XXX companies to date.
Last acquisition by Dr. Reddy's Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Dr. Reddy's Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Dr. Reddy's Laboratories founded? | Dr. Reddy's Laboratories was founded in 1984. |
| Where is Dr. Reddy's Laboratories headquartered? | Dr. Reddy's Laboratories is headquartered in India. |
| How many employees does Dr. Reddy's Laboratories have? | As of today, Dr. Reddy's Laboratories has 27.0K+ employees. |
| Who is the CEO of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories's CEO is Mr. M. V. Ramana. |
| Is Dr. Reddy's Laboratories publicy listed? | Yes, Dr. Reddy's Laboratories is a public company listed on BOM. |
| What is the stock symbol of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories trades under 500124 ticker. |
| When did Dr. Reddy's Laboratories go public? | Dr. Reddy's Laboratories went public in 1992. |
| Who are competitors of Dr. Reddy's Laboratories? | Similar companies to Dr. Reddy's Laboratories include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories's current market cap is $10.7B |
| What is the current revenue of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories's last 12-month revenue is $3.8B. |
| What is the current EBITDA of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories's last 12-month EBITDA is $1.0B. |
| What is the current EV/Revenue multiple of Dr. Reddy's Laboratories? | Current revenue multiple of Dr. Reddy's Laboratories is 2.8x. |
| What is the current EV/EBITDA multiple of Dr. Reddy's Laboratories? | Current EBITDA multiple of Dr. Reddy's Laboratories is 10.3x. |
| What is the current revenue growth of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories revenue growth between 2023 and 2024 was 14%. |
| Is Dr. Reddy's Laboratories profitable? | Yes, Dr. Reddy's Laboratories is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
